Regencell Bioscience (NASDAQ:RGC) Hits New 12-Month Low – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price reached a new 52-week low during trading on Tuesday . The stock traded as low as $4.92 and last traded at $5.05, with a volume of 474147 shares changing hands. The stock had previously closed at $5.88.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Regencell Bioscience Stock Performance

The firm has a 50 day moving average of $18.15 and a 200-day moving average of $24.65.

Regencell Bioscience (NASDAQ:RGC) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.00) EPS for the quarter.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RGC. Squarepoint Ops LLC bought a new position in Regencell Bioscience in the second quarter worth $1,701,000. BNP Paribas Financial Markets bought a new stake in Regencell Bioscience in the 2nd quarter valued at $768,000. XTX Topco Ltd bought a new stake in Regencell Bioscience in the 3rd quarter valued at $598,000. Vident Advisory LLC raised its stake in shares of Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after buying an additional 17,143 shares in the last quarter. 0.13% of the stock is currently owned by institutional investors and hedge funds.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.